Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IBI334 |
| Synonyms | |
| Therapy Description |
IBI334 is a bispecific antibody that targets EGFR and CD276 (B7-H3), which potentially induces antitumor activity (Cancer Res (2024) 84 (7_Supplement): LB056). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IBI334 | IBI-334|IBI 334 | CD276 Antibody 21 EGFR Antibody 73 | IBI334 is a bispecific antibody that targets EGFR and CD276 (B7-H3), which potentially induces antitumor activity (Cancer Res (2024) 84 (7_Supplement): LB056). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05774873 | Phase I | IBI334 | IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | Recruiting | AUS | 0 |